Silverarc Capital Management LLC Has $3.65 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Silverarc Capital Management LLC boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 64.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,955 shares of the company's stock after purchasing an additional 25,955 shares during the period. Silverarc Capital Management LLC owned 0.17% of Tarsus Pharmaceuticals worth $3,652,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $25,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals in the fourth quarter worth approximately $53,000. HighTower Advisors LLC bought a new position in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $207,000. Summit Investment Advisors Inc. lifted its stake in Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth approximately $223,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

TARS traded up $0.03 during midday trading on Friday, reaching $50.00. The company's stock had a trading volume of 754,503 shares, compared to its average volume of 689,977. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The stock has a market cap of $1.92 billion, a P/E ratio of -13.12 and a beta of 0.94. The company has a fifty day simple moving average of $47.60 and a 200 day simple moving average of $48.34. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

TARS has been the subject of several analyst reports. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Barclays decreased their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $63.67.

Insider Buying and Selling

In other news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 824,106 shares in the company, valued at approximately $41,205,300. This represents a 0.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the sale, the insider now directly owns 50,751 shares in the company, valued at approximately $2,349,263.79. The trade was a 4.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock valued at $1,581,173 over the last three months. 8.25% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.